Clinical Trial Update: Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update of camrelizumab plus chemotherapy as neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Esophageal Carcinoma | Phase 2 | Status: UNKNOWN